MetaCap

CytoMed Therapeutics (GDTC) vs Lexaria Bioscience (LEXX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CytoMed Therapeutics is the larger company by market cap ($9.0 million vs $8.5 million), about 1.1 times the size. CytoMed Therapeutics converts more of its revenue into profit, with a net margin of -1227.1% versus -1686.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GDTC-22.96%LEXX+16.47%
+38%+5%-28%
Oct 7, 20261 yearNov 20, 2026
GDTC-15.17%LEXX+21.39%
+38%+10%-18%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GDTC versus LEXX key metrics
MetricGDTCLEXX
Share price$0.755$4.03
Market cap$9.01M$8.49M
1-day change-2.33%-10.24%
YTD return-43.45%—
1-year return-59.84%—
EPS (TTM)$-0.23$-5.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$252.26K$705.92K
Revenue growth (YoY)+395.88%+52.05%
Net income (latest FY)$-3.10M$-11.90M
Gross margin—99.61%
Operating margin—-1683.01%
Net margin-1227.07%-1686.00%
52-week high$2.12$21.60
52-week low$0.68$2.43
Distance from 52-week high-64.39%-81.34%
Analyst consensusnonenone
Avg. price target upside+450.99%+1947.15%
Average volume15.69K70.52K
Shares outstanding11.93M2.11M
Employees427
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CytoMed Therapeutics is more profitable, keeping -1227.1 cents of every revenue dollar as net income versus -1686.0 cents for Lexaria Bioscience.
  • CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +52.05%).

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

GDTC vs LEXX FAQ

Which is bigger, CytoMed Therapeutics or Lexaria Bioscience?

CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $9.01M compared with $8.49M for Lexaria Bioscience (LEXX).

Are CytoMed Therapeutics and Lexaria Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons